Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AARD NASDAQ:ENTA NASDAQ:JSPR NASDAQ:MDWD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$8.00+1.1%$11.19$4.88▼$19.58$171.62MN/A104,489 shs617,170 shsENTAEnanta Pharmaceuticals$8.33-7.9%$7.83$4.09▼$13.37$193.26M0.84148,218 shs218,809 shsJSPRJasper Therapeutics$2.58-0.4%$3.15$2.27▼$26.05$42.10M2.77158,902 shs74,428 shsMDWDMediWound$18.45+13.3%$18.62$14.14▼$22.50$176.06M0.25103,129 shs554,666 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics-3.54%-10.72%-34.03%-29.94%+790,999,900.00%ENTAEnanta Pharmaceuticals+1.46%+0.44%+31.01%+13.71%-22.27%JSPRJasper Therapeutics-2.26%-6.16%+5.71%-53.75%-86.58%MDWDMediWound-2.69%-1.87%-12.56%-21.00%-3.04%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$8.00+1.1%$11.19$4.88▼$19.58$171.62MN/A104,489 shs617,170 shsENTAEnanta Pharmaceuticals$8.33-7.9%$7.83$4.09▼$13.37$193.26M0.84148,218 shs218,809 shsJSPRJasper Therapeutics$2.58-0.4%$3.15$2.27▼$26.05$42.10M2.77158,902 shs74,428 shsMDWDMediWound$18.45+13.3%$18.62$14.14▼$22.50$176.06M0.25103,129 shs554,666 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics-3.54%-10.72%-34.03%-29.94%+790,999,900.00%ENTAEnanta Pharmaceuticals+1.46%+0.44%+31.01%+13.71%-22.27%JSPRJasper Therapeutics-2.26%-6.16%+5.71%-53.75%-86.58%MDWDMediWound-2.69%-1.87%-12.56%-21.00%-3.04%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAARDAardvark Therapeutics 3.00Buy$32.60307.50% UpsideENTAEnanta Pharmaceuticals 3.00Buy$22.25167.11% UpsideJSPRJasper Therapeutics 2.60Moderate Buy$28.751,014.34% UpsideMDWDMediWound 2.80Moderate Buy$32.2574.80% UpsideCurrent Analyst Ratings BreakdownLatest JSPR, MDWD, AARD, and ENTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/2/2025ENTAEnanta PharmaceuticalsWestpark CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$24.008/28/2025AARDAardvark TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$26.00 ➝ $25.008/19/2025MDWDMediWoundZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/15/2025JSPRJasper TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$29.00 ➝ $25.008/14/2025AARDAardvark TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$20.00 ➝ $19.008/12/2025ENTAEnanta PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$24.00 ➝ $25.007/28/2025ENTAEnanta PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$20.007/8/2025JSPRJasper TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Sector Perform$5.007/8/2025JSPRJasper TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$70.00 ➝ $12.007/8/2025JSPRJasper TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$50.00 ➝ $20.007/8/2025JSPRJasper TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAARDAardvark TherapeuticsN/AN/AN/AN/AN/AN/AENTAEnanta Pharmaceuticals$67.64M2.63N/AN/A$6.08 per share1.37JSPRJasper TherapeuticsN/AN/AN/AN/A$4.11 per shareN/AMDWDMediWound$20.22M9.86N/AN/A$2.89 per share6.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAARDAardvark Therapeutics-$20.59MN/A0.00∞N/AN/AN/AN/AN/AENTAEnanta Pharmaceuticals-$116.04M-$4.32N/AN/AN/A-141.98%-89.02%-27.28%11/24/2025 (Estimated)JSPRJasper Therapeutics-$71.27M-$6.01N/AN/AN/AN/A-172.28%-128.34%11/6/2025 (Estimated)MDWDMediWound-$30.22M-$2.64N/AN/AN/A-142.18%-96.71%-39.73%11/25/2025 (Estimated)Latest JSPR, MDWD, AARD, and ENTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025MDWDMediWound-$0.55-$1.23-$0.68-$1.23$5.68 million$5.71 million8/13/2025Q2 2025AARDAardvark Therapeutics-$0.52-$0.66-$0.14-$0.66N/AN/A8/13/2025Q2 2025JSPRJasper Therapeutics-$1.20-$1.74-$0.54-$1.74N/AN/A8/11/2025Q3 2025ENTAEnanta Pharmaceuticals-$1.25-$0.85+$0.40-$0.85$16.21 million$18.31 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAARDAardvark TherapeuticsN/AN/AN/AN/AN/AENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AJSPRJasper TherapeuticsN/AN/AN/AN/AN/AMDWDMediWoundN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAARDAardvark TherapeuticsN/A14.0414.04ENTAEnanta PharmaceuticalsN/A5.005.00JSPRJasper TherapeuticsN/A2.102.10MDWDMediWoundN/A1.481.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAARDAardvark TherapeuticsN/AENTAEnanta Pharmaceuticals94.99%JSPRJasper Therapeutics79.85%MDWDMediWound46.83%Insider OwnershipCompanyInsider OwnershipAARDAardvark TherapeuticsN/AENTAEnanta Pharmaceuticals13.89%JSPRJasper Therapeutics4.60%MDWDMediWound9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAARDAardvark Therapeutics1821.70 millionN/AN/AENTAEnanta Pharmaceuticals16021.38 million18.41 millionOptionableJSPRJasper Therapeutics2016.25 million15.51 millionOptionableMDWDMediWound8010.81 million9.81 millionOptionableJSPR, MDWD, AARD, and ENTA HeadlinesRecent News About These CompaniesMediWound’s NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association CongressSeptember 2, 2025 | markets.businessinsider.comMediWound's NexoBrid® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association CongressSeptember 2, 2025 | globenewswire.comMediWound Is A Buy Opportunity On The DipSeptember 2, 2025 | seekingalpha.comMediWound (NASDAQ:MDWD) Downgraded to "Hold" Rating by Zacks ResearchAugust 23, 2025 | marketbeat.comMediWound to Present at the H.C. Wainwright 27th Annual Global ...August 22, 2025 | morningstar.comMMediWound to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceAugust 20, 2025 | globenewswire.comMediWound Executives Purchase Shares, Signaling ConfidenceAugust 19, 2025 | msn.comMediWound (NASDAQ:MDWD) Posts Quarterly Earnings Results, Misses Expectations By $0.68 EPSAugust 18, 2025 | marketbeat.comCraig-Hallum Sticks to Their Buy Rating for Mediwound (MDWD)August 17, 2025 | theglobeandmail.comAnalysts Have Made A Financial Statement On MediWound Ltd.'s (NASDAQ:MDWD) Second-Quarter ReportAugust 17, 2025 | finance.yahoo.comMediWound reports Q2 EPS ($1.23), consensus (57c)August 14, 2025 | msn.comMediWound Revenue Jumps 43% in Q2August 14, 2025 | aol.comAMediWound Reports Q2 2025 Financial Results and Strategic UpdatesAugust 14, 2025 | msn.comMediWound Ltd. (MDWD) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | seekingalpha.comMediWound (MDWD) Reports Q2 Loss, Beats Revenue EstimatesAugust 14, 2025 | zacks.comMediWound Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 14, 2025 | globenewswire.comMediWound Q2 2025 Earnings PreviewAugust 13, 2025 | msn.comMediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg UlcersAugust 13, 2025 | globenewswire.comMediWound Ltd. to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 14August 4, 2025 | quiverquant.comQMediWound to Report Second Quarter 2025 Financial ResultsAugust 4, 2025 | globenewswire.comHere's What Could Help MediWound (MDWD) Maintain Its Recent Price StrengthJuly 24, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJSPR, MDWD, AARD, and ENTA Company DescriptionsAardvark Therapeutics NASDAQ:AARD$8.00 +0.09 (+1.14%) As of 04:00 PM EasternAardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.Enanta Pharmaceuticals NASDAQ:ENTA$8.33 -0.71 (-7.85%) Closing price 04:00 PM EasternExtended Trading$8.34 +0.01 (+0.17%) As of 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Jasper Therapeutics NASDAQ:JSPR$2.58 -0.01 (-0.39%) Closing price 04:00 PM EasternExtended Trading$2.58 0.00 (-0.19%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.MediWound NASDAQ:MDWD$18.45 +2.16 (+13.26%) Closing price 04:00 PM EasternExtended Trading$18.95 +0.50 (+2.74%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Part of the Club: Robinhood & AppLovin Soar on S&P 500 Inclusion Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
